CatenaBio’s CysTyr platform enables site‑specific conjugation of two or more drug payloads to a single antibody using a stable cystine‑tyrosine (C‑Y) bond. The resulting multi‑payload ADCs support flexible drug‑to‑antibody ratios and accommodate large or complex molecules, aiming to overcome resistance and improve therapeutic index in solid‑tumor indications. The technology integrates with existing antibody manufacturing processes for pharmaceutical and biotech developers.
Funding
Funding not disclosed
Founders
Product
Problem
Current antibody‑drug conjugates (ADCs) are limited to a single small‑molecule payload, which contributes to resistance and relapse in solid‑tumor patients. Existing conjugation chemistries also restrict payload size and often suffer from premature linker‑payload release, reducing therapeutic efficacy and safety.
Solution
CatenaBio’s CysTyr platform creates Multi‑Payload Conjugates (MPCs) that attach two or more distinct payloads to a single antibody with precise site control. The platform leverages a novel cystine‑tyrosine (C‑Y) bond to form a chemically stable linkage that resists off‑target release. By allowing flexible drug‑to‑antibody ratios (DAR) and supporting payloads of any size or complexity, the MPCs aim to overcome resistance mechanisms and improve the therapeutic index for solid‑tumor indications. Preclinical data show enhanced potency compared with conventional single‑payload ADCs, positioning the technology as a next‑generation solution for oncology drug development.
Target Audience
The primary customers are pharmaceutical and biotechnology companies developing ADC‑based oncology therapies, particularly those focused on solid tumors with high unmet medical need.
Features
- C‑Y Bond™ chemistry creates a covalent cystine‑tyrosine linkage that is more stable than traditional maleimide bonds, reducing premature payload release.
- Site‑specific conjugation enables precise control over attachment locations on the antibody, supporting flexible DAR configurations.
- Multi‑payload capability allows simultaneous incorporation of two or more drugs, including large or complex molecules, expanding therapeutic options beyond small‑molecule payloads.
- Dual‑payload design targets complementary mechanisms of action to mitigate resistance and improve tumor cell kill in solid‑tumor models.
- Preclinical studies demonstrate superior efficacy and safety profiles relative to standard ADCs.
- Platform is compatible with existing antibody manufacturing workflows, facilitating integration into current biopharma pipelines.